News

Hosted on MSN2mon
FDA approves SPRAVATO as first monotherapy for MDD
TITUSVILLE, N.J. - Johnson & Johnson (NYSE:JNJ) has received approval from the U.S. Food and Drug Administration (FDA) for SPRAVATO® (esketamine) nasal spray as a standalone treatment for adults ...
Cybin wins new Buy from Guggenheim: potential to challenge J&J’s Spravato cited
Guggenheim has initiated its coverage of psychedelic drug developer Cybin (NYSE:CYBN) with a Buy rating and a $35 per share ...